Current Document Type: HighlightsVideoPage IDH-Mutated AML Beyond Enasidenib and Ivosidenib Monotherapy - JADPRO

Watch More Highlights

Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses important updates that advanced practitioners need to be aware of when treating patients with acute myeloid leukemia, including two key driver mutations (IDH1 and IDH2), the inhibitors ivosidenib and enasidenib, lower-intensity chemotherapy combinations, and the role of venetoclax and azacitidine.

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.